These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 2758413

  • 1. Modulatory potency of the beta-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients.
    Hajto T, Hostanska K, Gabius HJ.
    Cancer Res; 1989 Sep 01; 49(17):4803-8. PubMed ID: 2758413
    [Abstract] [Full Text] [Related]

  • 2. Inability of galactoside-specific mistletoe lectin to inhibit N-methyl-N-nitrosourea-induced tumor development in the urinary bladder of rats and to mediate a local cellular immune response after long-term administration.
    Kunze E, Schulz H, Gabius HJ.
    J Cancer Res Clin Oncol; 1998 Sep 01; 124(2):73-87. PubMed ID: 9654190
    [Abstract] [Full Text] [Related]

  • 3. [Detection and quantitative determination of lectins and viscotoxins in mistletoe preparations].
    Jordan E, Wagner H.
    Arzneimittelforschung; 1986 Mar 01; 36(3):428-33. PubMed ID: 3707660
    [Abstract] [Full Text] [Related]

  • 4. Immunomodulatory effects of iscador: a Viscum album preparation.
    Hajto T.
    Oncology; 1986 Mar 01; 43 Suppl 1():51-65. PubMed ID: 2433654
    [Abstract] [Full Text] [Related]

  • 5. Further refinement of the description of the ligand-binding characteristics for the galactoside-binding mistletoe lectin, a plant agglutinin with immunomodulatory potency.
    Galanina OE, Kaltner H, Khraltsova LS, Bovin NV, Gabius HJ.
    J Mol Recognit; 1997 Mar 01; 10(3):139-47. PubMed ID: 9408830
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. From ill-defined extracts to the immunomodulatory lectin: will there be a reason for oncological application of mistletoe?
    Gabius HJ, Gabius S, Joshi SS, Koch B, Schroeder M, Manzke WM, Westerhausen M.
    Planta Med; 1994 Feb 01; 60(1):2-7. PubMed ID: 8134410
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term administration of galactoside-specific mistletoe lectin in an animal model: no protection against N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder carcinogenesis in rats and no induction of a relevant local cellular immune response.
    Kunze E, Schulz H, Adamek M, Gabius HJ.
    J Cancer Res Clin Oncol; 2000 Mar 01; 126(3):125-38. PubMed ID: 10741906
    [Abstract] [Full Text] [Related]

  • 10. The immunomodulatory beta-galactoside-specific lectin from mistletoe: partial sequence analysis, cell and tissue binding, and impact on intracellular biosignalling of monocytic leukemia cells.
    Gabius HJ, Walzel H, Joshi SS, Kruip J, Kojima S, Gerke V, Kratzin H, Gabius S.
    Anticancer Res; 1992 Mar 01; 12(3):669-75. PubMed ID: 1622124
    [Abstract] [Full Text] [Related]

  • 11. Structure and properties of polysaccharides from Viscum album (L.).
    Jordan E, Wagner H.
    Oncology; 1986 Mar 01; 43 Suppl 1():8-15. PubMed ID: 3808577
    [Abstract] [Full Text] [Related]

  • 12. Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces beta-endorphin release and immunopotentiation in breast cancer patients.
    Heiny BM, Beuth J.
    Anticancer Res; 1994 Mar 01; 14(3B):1339-42. PubMed ID: 8067703
    [Abstract] [Full Text] [Related]

  • 13. Effect of a recombinant lectin, Viscum album agglutinin on the secretion of interleukin-12 in cultured human peripheral blood mononuclear cells and on NK-cell-mediated cytotoxicity of rat splenocytes in vitro and in vivo.
    Hajto T, Hostanska K, Weber K, Zinke H, Fischer J, Mengs U, Lentzen H, Saller R.
    Nat Immun; 1998 Mar 01; 16(1):34-46. PubMed ID: 9789123
    [Abstract] [Full Text] [Related]

  • 14. Studies on the standardization of mistletoe preparations.
    Wagner H, Jordan E, Feil B.
    Oncology; 1986 Mar 01; 43 Suppl 1():16-22. PubMed ID: 3027640
    [Abstract] [Full Text] [Related]

  • 15. Respiratory burst of human polymorphonuclear leukocytes in response to the galactoside-specific mistletoe lectin.
    Braun JM, Gemmell CG, Beuth J, Ko HL, Pulverer G.
    Zentralbl Bakteriol; 1995 Nov 01; 283(1):90-4. PubMed ID: 9810649
    [Abstract] [Full Text] [Related]

  • 16. Influence of treatment with the immunomodulatory effective dose of the beta-galactoside-specific lectin from mistletoe on tumor colonization in BALB/c-mice for two experimental model systems.
    Beuth J, Ko HL, Gabius HJ, Pulverer G.
    In Vivo; 1991 Nov 01; 5(1):29-32. PubMed ID: 1932621
    [Abstract] [Full Text] [Related]

  • 17. Carbohydrate-binding proteins (plant/human lectins and autoantibodies from human serum) as mediators of release of lysozyme, elastase, and myeloperoxidase from human neutrophils.
    Timoshenko AV, Kayser K, Drings P, André S, Dong X, Kaltner H, Schneller M, Gabius HJ.
    Res Exp Med (Berl); 1995 Nov 01; 195(3):153-62. PubMed ID: 8570910
    [Abstract] [Full Text] [Related]

  • 18. Characterization of cytotoxic proteins from mistletoe (Viscum album L.).
    Jung ML, Baudino S, Ribéreau-Gayon G, Beck JP.
    Cancer Lett; 1990 May 30; 51(2):103-8. PubMed ID: 2344587
    [Abstract] [Full Text] [Related]

  • 19. Characterization of a toxic lectin in Iscador, a mistletoe preparation with alleged cancerostatic properties.
    Holtskog R, Sandvig K, Olsnes S.
    Oncology; 1988 May 30; 45(3):172-9. PubMed ID: 3368193
    [Abstract] [Full Text] [Related]

  • 20. Evidence for stimulation of tumor proliferation in cell lines and histotypic cultures by clinically relevant low doses of the galactoside-binding mistletoe lectin, a component of proprietary extracts.
    Gabius HJ, Darro F, Remmelink M, André S, Kopitz J, Danguy A, Gabius S, Salmon I, Kiss R.
    Cancer Invest; 2001 May 30; 19(2):114-26. PubMed ID: 11296616
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.